Drug intelligence / Profile preview

ABB i5

Development stage: Unknown
Modality: Microbiome Therapeutics
Administration: Oral

Overview

ABB i5 is a prebiotic, a type of dietary supplement designed to selectively stimulate the growth and/or activity of beneficial microorganisms in the gut. It is being investigated for its potential to manage constipation and improve overall gastrointestinal well-being through its effects on the gut microbiota. It has been studied in a pilot trial in combination with the postbiotic ABB C22.

Beyond the preview

Go deeper on ABB i5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABB i5.

Explore the full profile